NCT01590446

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

A Phase 1, Two-Part, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMN 111 Administered to Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 74 (estimated)
• Sponsor: BioMarin Pharmaceutical · Industry
• Sex: Male
• Age: 22 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to measure how much of the study drug gets into the blood- stream and how long it takes the body to get rid of it when given as a single dose. Information about any side effects that may occur will also be collected.

Conditions

• Achondroplasia

Interventions

Type	Name	Description
DRUG	BMN 111	SC injection, Part 1 single dose and Part 2 multiple dose.
DRUG	Normal Saline	SC injection, Part 1 single dose and Part 2 multiple dose

Timeline

• Start date: 2012-02-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2012-05-03
• Last updated: 2012-06-11

Locations

1 site across 1 country: United States